High rate of clinical recurrence in patients with Vogt–Koyanagi–Harada disease treated with early high-dose corticosteroids

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 253, Issue 5, 2015, Pages 785-790

  Sakata, Viviane M ^a   da Silva, Felipe T ^b   Hirata, Carlos E ^a   Marin, Maria Lucia C ^a   Rodrigues, Helcio ^a   Kalil, Jorge ^a   Costa, Rogerio A ^a,c   Yamamoto, Joyce H ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDADE DO PLANALTO CATARINENSE   (Brazil)

^c Division of Macula Imaging and Treatment   (Brazil)

Author keywords

Clinical course; Disease outcome; Subretinal fibrosis; Vogt Koyanagi Harada disease

Indexed keywords

GLUCOCORTICOID; HLA DRB1 ANTIGEN; HLA-DRB1*04:05 ANTIGEN; METHYLPREDNISOLONE; PREDNISONE;

ADOLESCENT; ADULT; BRAZIL; CHILD; CHRONIC DISEASE; DRUG PULSE THERAPY; FEMALE; FIBROSIS; FLUORESCENCE ANGIOGRAPHY; GENETICS; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; RECURRENT DISEASE; RETINA; RETROSPECTIVE STUDY; UVEOMENINGOENCEPHALITIC SYNDROME; YOUNG ADULT;

ADOLESCENT; ADULT; BRAZIL; CHILD; CHRONIC DISEASE; FEMALE; FIBROSIS; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HLA-DRB1 CHAINS; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDNISONE; PROGNOSIS; PULSE THERAPY, DRUG; RECURRENCE; RETINA; RETROSPECTIVE STUDIES; UVEOMENINGOENCEPHALITIC SYNDROME; YOUNG ADULT;

EID: 84939998098     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-014-2904-z     Document Type: Article

References (21)

1. Rubsamen PE, Gass JE (1991) Vogt–Koyanagi–Harada syndrome clinical course, therapy and long-term visual outcome. Arch Ophthalmol 11:682–687
2. Moorthy RS, Inomata H, Rao NA (1995) Major review Vogt–Koyanagi–Harada syndrome. Surv Ophthalmol 39:265–292
3. Al-Kharashi AS, Aldibhi H, Al-Fraykh H, Kangave D, Abu El-Asrar AM (2007) Prognostic factors in Vogt–Koyanagi–Harada disease. Int Ophthalmol 27:201–210
4. Chee S-P, Jap A, Bacsal K (2009) Prognostic factors of Vogt–Koyanagi–Harada disease in Singapore. Am J Ophthalmol 147:154–161
5. Abu El-Asrar AM, Al Tamimi M, Hemachandran S, Al-Mezaine HS, Al-Muammar A, Kangave D (2013) Prognostic factors for clinical outcomes in patients with Vogt–Koyanagi–Harada disease treated with high-dose corticosteroids. Acta Ophthalmol 91:e486–e493
6. da Silva FTBGC, Damico FM, Marin ML, Goldberg AC, Hirata CE, Olivalves E, Yamamoto JH (2009) Revised diagnostic criteria for Vogt–Koyanagi–Harada disease: considerations on the different disease categories. Am J Ophthalmol 147:339.e5–345.e5
7. Chee S-P, Jap A, Bacsal K (2007) Spectrum of Vogt–Koyanagi–Harada disease in Singapore. Int Ophthalmol 27:137–142
8. Tugal-Tutkun I, Ozyazgan Y, Akova Y, Sullu Y, Akyol N, Soylu M, Kazokoglu H (2007) The spectrum of Vogt–Koyanagi–Harada disease in Turkey: VKH in Turkey. Int Ophthalmol 27:117–123
9. Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-garcia L, Pivetti-pezzi P, Tessler HH, Usui M (2001) Revised diagnostic criteria for Vogt–Koyanagi–Harada disease. Am J Ophthalmol 131:647–652
10. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140:509–516
11. Kuo IC, Rechdouni A, Rao NA, Johnston RH, Margolis TP, Cunningham ET (2000) Subretinal fibrosis in patients with Vogt–Koyanagi–Harada disease. Ophthalmology 107:1721–1728
12. Bignon JD, Fernandez-Vina MA (1997) Protocols of the 12th international histocompatibility workshop for typing of HLA class II alleles by DNA amplification by the polymerase chain reaction (PCR) and hybridization with sequence specific oligonucleotide probes (SSOP). In: Charron D (ed) Genetic diversity of HLA, functional and medical implications. EDK, Paris, pp 584–595
13. Lertsumitkul S, Whitcup SM, Nussenblatt RB, Chan CC (1999) Subretinal fibrosis and choroidal neovascularization in Vogt–Koyanagi–Harada syndrome. Graefes Arch Clin Exp Ophthalmol 237:1039–1045
14. da Silva FT, Hirata CE, Olivalves E, Oyamada MK, Yamamoto JH (2009) Fundus-based and electroretinographic strategies for stratification of late-stage Vogt–Koyanagi–Harada disease patients. Am J Ophthalmol 148:939.e3–945.e3
15. Gass JDM, Margo CE, Levy MH (1996) Progressive subretinal fibrosis and blindness in patients with multifocal granulomatous chorioretinitis. Am J Ophthalmol 122:76–85
16. Sternberg P Jr, Machemer R (1984) Subretinal proliferation. Am J Ophthalmol 98:456–462
17. Green W, Enger C (2005) Age related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture. Retina 25:1519–1535
18. Goldberg AC, Yamamoto JH, ChiarellaJ M, Marin ML, Sibinelli M, Neufeld R, Hirata CE, Olivalves E, Kalil J (1998) HLA-DRB1*0405 is the predominant allele in Brazilian patients with Vogt–Koyanagi–Harada disease. Hum Immunol 59:183–188
19. Damico FM, Cunha-Neto E, Goldberg AC, Iwai LK, Marin ML, Hammer J, Kalil J, Yamamoto JH (2005) T-cell recognition and cytokine profile induced by melanocyte epitopes in patients with HLA-DRB1*0405-positive and -negative Vogt–Koyanagi–Harada uveitis. Invest Ophthalmol Vis Sci 46:2465–2471
20. Islam SM, Numaga J, Matsuki K, Fujino Y, Maeda H, Masuda K (1994) Influence of HLA-DRB1 gene variation on the clinical course of Vogt–Koyanagi–Harada disease. Invest Ophthalmol Vis Sci 35:752–756
21. Kim MH, Seong MC, Kwak NH, Yoo JS, Huh W, Kim TG, Han H (2000) Association of HLA with Vogt–Koyanagi–Harada syndrome in Koreans. Am J Ophthalmol 129:173–177